Overview
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid peptide present in virtually all human cells. It is the second pillar of the regenerative peptide world, usually discussed alongside BPC-157 — the famous Wolverine stack combines both.
Like BPC-157, the evidence base is almost entirely preclinical, though thymosin beta-4 itself has been in human trials for wound healing and cardiac repair.
How It Works
Thymosin beta-4 regulates actin, a protein fundamental to cell structure and movement. By modulating actin polymerization, it promotes cell migration to injury sites — the first step of tissue repair.
Broad regenerative signaling
The peptide also reduces inflammation, promotes angiogenesis, and inhibits fibrosis (scar tissue formation). This combination — more blood vessels, more repair cells, less scarring — explains its reputation for flexibility and range-of-motion improvements in chronically stiff tissues.
Key Benefits
Soft tissue repair — animal models show accelerated healing of muscle, tendon and ligament injuries.
Reduced fibrosis — less scar tissue means more functional, flexible healed tissue.
Cardiac repair — thymosin beta-4 has human trial data in heart attack recovery, the most advanced clinical evidence in this family.
Flexibility — the most consistently reported anecdotal benefit, likely from reduced adhesions.
Side Effects & Considerations
Human safety data for TB-500 specifically is lacking. The parent molecule has passed early-phase human trials without major signals, but that does not establish safety for chronic grey-market use.
The cancer question
Because thymosin beta-4 is involved in cell migration, researchers have studied its role in tumor metastasis. Evidence is mixed and unresolved — anyone with a personal or strong family history of cancer should treat this as a serious unknown. TB-500 is WADA prohibited and not approved for human use.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Loading (anecdotal) | 2-2.5 mg | Twice weekly | 4-6 weeks | Subcutaneous. Community convention — no human dosing studies exist. |
| Maintenance | 2 mg | Once weekly or biweekly | As needed | Used after the loading phase for chronic issues. |
Warnings
No approved human use. WADA prohibited. Unresolved theoretical concerns regarding cell migration and cancer.